A recent ASCO (2022) study demonstrated that mobocertinib and amivantamab had similar efficacy in NSCLC patients with EGFR ex20ins who had disease progression during or after platinum-based chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.